New Delhi, October 01, 2014 – The Delhi High Court today asked the National Pharmaceutical Pricing Authority (NPPA) to show the manner in which it is exercising its power to cap prices of non-scheduled drugs in view of the recent withdrawal of the guidelines issued for the purpose.
The NPPA had on the basis of the May 29 guideline issued a notification on July 10 capping prices of 108 anti-diabetic and cardiovascular drugs.
The NPPA submitted before the court that only some internal guidelines were withdrawn and the same would not in any way affect the July 10 notification.
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…